127 related articles for article (PubMed ID: 34980779)
1. Imatinib Mesylate Exerted Antitumor Effect by Promoting Infiltration of Effector T Cells in Tumor.
Hirata A; Sawai E; Henmi M; Shibasaki C; Mizoguchi Y; Narumi K; Aoki K
Biol Pharm Bull; 2022; 45(1):34-41. PubMed ID: 34980779
[TBL] [Abstract][Full Text] [Related]
2. Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells.
Tanaka A; Nishikawa H; Noguchi S; Sugiyama D; Morikawa H; Takeuchi Y; Ha D; Shigeta N; Kitawaki T; Maeda Y; Saito T; Shinohara Y; Kameoka Y; Iwaisako K; Monma F; Ohishi K; Karbach J; Jäger E; Sawada K; Katayama N; Takahashi N; Sakaguchi S
J Exp Med; 2020 Feb; 217(2):. PubMed ID: 31704808
[TBL] [Abstract][Full Text] [Related]
3. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
Wang D; Jiang W; Zhu F; Mao X; Agrawal S
Int J Oncol; 2018 Sep; 53(3):1193-1203. PubMed ID: 29956749
[TBL] [Abstract][Full Text] [Related]
4. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine Kinase Inhibition Alters Intratumoral CD8+ T-cell Subtype Composition and Activity.
Tieniber AD; Hanna AN; Medina BD; Vitiello GA; Etherington MS; Liu M; Do KJ; Rossi F; DeMatteo RP
Cancer Immunol Res; 2022 Oct; 10(10):1210-1223. PubMed ID: 35917579
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous inoculation position affects the immune environment in CT26 carcinomas.
Fu X; Yang Y; Xie J; Pan X; Yang X; Du Z; Hao E
Biochem Biophys Res Commun; 2019 Apr; 512(2):244-249. PubMed ID: 30879760
[TBL] [Abstract][Full Text] [Related]
7.
Liang R; Li P; Yang N; Xiao X; Gong J; Zhang X; Bai Y; Chen Y; Xie Z; Liao Q
Drug Des Devel Ther; 2024; 18():1833-1853. PubMed ID: 38828018
[TBL] [Abstract][Full Text] [Related]
8. A novel co-culture assay to assess anti-tumor CD8
Olivo Pimentel V; Yaromina A; Marcus D; Dubois LJ; Lambin P
J Immunol Methods; 2020 Dec; 487():112899. PubMed ID: 33068606
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity and immune response induction of a dual agonist of Toll-like receptors 7 and 8.
Wang D; Precopio M; Lan T; Yu D; Tang JX; Kandimalla ER; Agrawal S
Mol Cancer Ther; 2010 Jun; 9(6):1788-97. PubMed ID: 20515950
[TBL] [Abstract][Full Text] [Related]
10. Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors.
Larmonier N; Janikashvili N; LaCasse CJ; Larmonier CB; Cantrell J; Situ E; Lundeen T; Bonnotte B; Katsanis E
J Immunol; 2008 Nov; 181(10):6955-63. PubMed ID: 18981115
[TBL] [Abstract][Full Text] [Related]
11. Adoptive transfer of anti-CD3-activated CD4+ T cells plus cyclophosphamide and liposome-encapsulated interleukin-2 cure murine MC-38 and 3LL tumors and establish tumor-specific immunity.
Saxton ML; Longo DL; Wetzel HE; Tribble H; Alvord WG; Kwak LW; Leonard AS; Ullmann CD; Curti BD; Ochoa AC
Blood; 1997 Apr; 89(7):2529-36. PubMed ID: 9116299
[TBL] [Abstract][Full Text] [Related]
12. Trichosanthin enhances anti-tumor immune response in a murine Lewis lung cancer model by boosting the interaction between TSLC1 and CRTAM.
Cai Y; Xiong S; Zheng Y; Luo F; Jiang P; Chu Y
Cell Mol Immunol; 2011 Jul; 8(4):359-67. PubMed ID: 21572449
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral interleukin-21 increases antitumor immunity, tumor-infiltrating CD8+ T-cell density and activity, and enlarges draining lymph nodes.
Søndergaard H; Galsgaard ED; Bartholomaeussen M; Straten PT; Odum N; Skak K
J Immunother; 2010 Apr; 33(3):236-49. PubMed ID: 20445344
[TBL] [Abstract][Full Text] [Related]
14. Exosomes from CIITA-transfected CT26 cells enhance anti- tumor effects.
Fan W; Tian XD; Huang E; Zhang JJ
Asian Pac J Cancer Prev; 2013; 14(2):987-91. PubMed ID: 23621273
[TBL] [Abstract][Full Text] [Related]
15. IFN-gamma can promote tumor evasion of the immune system in vivo by down-regulating cellular levels of an endogenous tumor antigen.
Beatty GL; Paterson Y
J Immunol; 2000 Nov; 165(10):5502-8. PubMed ID: 11067903
[TBL] [Abstract][Full Text] [Related]
16. Forced Expression of CXCL10 Prevents Liver Metastasis of Colon Carcinoma Cells by the Recruitment of Natural Killer Cells.
Kikuchi N; Ye J; Hirakawa J; Kawashima H
Biol Pharm Bull; 2019 Jan; 42(1):57-65. PubMed ID: 30381616
[TBL] [Abstract][Full Text] [Related]
17. Fractalkine transgene induces T-cell-dependent antitumor immunity through chemoattraction and activation of dendritic cells.
Guo J; Zhang M; Wang B; Yuan Z; Guo Z; Chen T; Yu Y; Qin Z; Cao X
Int J Cancer; 2003 Jan; 103(2):212-20. PubMed ID: 12455035
[TBL] [Abstract][Full Text] [Related]
18. CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination.
Casares N; Arribillaga L; Sarobe P; Dotor J; Lopez-Diaz de Cerio A; Melero I; Prieto J; Borrás-Cuesta F; Lasarte JJ
J Immunol; 2003 Dec; 171(11):5931-9. PubMed ID: 14634104
[TBL] [Abstract][Full Text] [Related]
19. The effect of CT26 tumor-derived TGF-β on the balance of tumor growth and immunity.
Owyang SY; Zhang M; Walkup GA; Chen GE; Grasberger H; El-Zaatari M; Kao JY
Immunol Lett; 2017 Nov; 191():47-54. PubMed ID: 28855127
[TBL] [Abstract][Full Text] [Related]
20. Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells.
Jarnicki AG; Lysaght J; Todryk S; Mills KH
J Immunol; 2006 Jul; 177(2):896-904. PubMed ID: 16818744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
